Flow cytometric analysis revealed a significant reduction in the number of IL-4-expressing CD8+ T-cells in tumors from dual IPI-549/PD-L1-treated tumor-bearing mice compared to IPI-549 single-agent treatment groups (Figure 7A). This evidence concerns the gene CD8A and neoplasm.